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Abstract
Background—Conflicting reports of the mortality risk among patients with psoriatic arthritis
(PsA) exist in the literature. The objective of this study was to examine the risk of mortality in
patients with PsA compared to matched controls and to patients with psoriasis and those with
rheumatoid arthritis (RA).
Methods—A longitudinal cohort study was performed in a large United Kingdom medical record
database,The Health Improvement Network (THIN), among patients with PsA, RA, or psoriasis
with data from 1994-2010. Unexposed controls were matched on practice and start date within the
practice for each patient with PsA. Cox proportional hazards models were used to calculate the
relative hazards for death.
Results—Patients with PsA (N=8,706), RA (N=41,752), psoriasis (N=138,424) and unexposed
controls (N=82,258) were identified; 1,442,357 person-years were observed during which 21,825
deaths occurred. Compared with population controls, patients with PsA did not have an increased
risk of mortality after adjusting for age and sex (DMARD users: HR 0.94, 95%CI: 0.80-1.10,
DMARD non-users: HR 1.06, 95%CI: 0.94-1.19) whereas RA patients had increased mortality
(DMARD users HR 1.59, 95%CI: 1.52-1.66, DMARD non-users HR 1.54, 95%CI: 1.47-1.60).
Patients with psoriasis who had not been prescribed a DMARD had a small increased risk of
mortality (HR 1.08, 95%CI: 1.04-1.12) while those who had been prescribed a DMARD,
indicating severe psoriasis, were at increased risk (HR 1.75, 95%CI: 1.56-1.95).
Conclusion—Patients with RA and psoriasis had elevated mortality compared to the general
population. However, patients with PsA did not have a significantly elevated risk of mortality.
Keywords
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Introduction
Psoriatic arthritis (PsA) is a chronic progressive inflammatory disease that affects over
500,000 Americans and can cause permanent joint damage and severe disability.(1)
However, it is unclear whether PsA confers an increased risk of mortality as, to date,
observational studies have yielded conflicting evidence.(2) Such studies have been limited
by small sample size with few events and the potential for selection bias in clinic-based
studies. Furthermore, very little is known about the risk of mortality in PsA from a
population based perspective.
Given that previous studies have demonstrated increased mortality among patients with
psoriasis and RA,(3,4) we hypothesized that patients with psoriatic arthritis would similarly
have increased rates of mortality compared to the general population. The objective of this
study was to measure the risk of all-cause mortality among patients with psoriatic arthritis as
compared to the general population and to patients with psoriasis only (without a diagnosis
of psoriatic arthritis) and rheumatoid arthritis.
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Methods
Study Design and Data Source
Acohort study was undertaken using data from The Health Improvement Network (THIN) in
the United Kingdom (UK) between 1994 and 2010. The UK is an ideal health system for
capturing medical record data as the general practitioner (GP) is the primary contact for all
aspects of the patient's care.(5) In the United Kingdom, 95% of patients are registered with a
general practitioner.(6) Participating GPs record data as a part of routine patient care (e.g.,
demographics, medical diagnoses, laboratory data, and prescriptions) in the electronic
medical record including recommendations made by specialists in secondary and tertiary
care. (However, some therapies may be initially prescribed by a specialist and often, the GP
will thereafter assume prescribing the medication. Tumor necrosis factor alpha prescriptions
are not generally recorded in THIN as these are exclusively prescribed by the specialist.)
The data are anonymized and collected by THIN, assessed for quality, and made available
for research use.(7) The Health Improvement Network draws patients from 514 general
practices and is representative of the United Kingdom population in terms of age, sex,
geography, and medical conditions.(8-11)
Study Population
All patients with PsA, psoriasis or RA between the ages of 18 and 89 at the start date were
included if they had observation time in THIN after Vision software implementation.
Patients were excluded if they died or transferred out of the practice prior to the
implementation of Vision software. Up to 10 unexposed controls from the general
population were randomly selected for each patient with PsA and were matched on practice
and start date within the practice. Unexposed controls were assigned a “diagnosis” date
within 6 months of the PsA patient's diagnosis date. This algorithm was designed to
minimize bias by ensuring that PsA and unexposed controls are followed by similar doctors
during similar time periods. Patients were not eligible to serve as unexposed controls if they
had PsA, psoriasis, or RA, or were utilizing disease modifying anti-rheumatic drugs
(DMARDs).
Person Time Calculation
Cohort entry was defined as the latest of diagnosis , six months after initial registration with
the practice, DMARD initiation, implementation of Vision software in the patient's practice,
or a practice acceptable mortality reporting.(7,12) (The first three are patient level factors
and last two are practice level factors). The rationale for choosing these elements is further
described in the online supplementary methods section. Censoring occurred when the patient
died, left the practice, the practice stopped participating in THIN, or study ended in
September 2010.
Exposure Definitions
PsA, psoriasis, and RA were defined by the presence of at least one READ code consistent
with these diseases. READ codes are a comprehensive hierarchical alphanumeric clinical
language developed in the UK to record diagnoses, symptoms, and tests, similar to
International Classification of Diseases (ICD) codes.(14) READ codes for psoriasis and
rheumatoid arthritis have been previously validated within the same or analogous large
medical record databases.(15-17) READ codes for psoriatic arthritis have a positive
predictive value of 85% as determined by survey of 100 randomly selected general
practitioners caring for patients with PsA.(18) We have also used this definition of PsA in
other studies.(19)
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Outcome Definition
The primary outcome, death, was defined by specific codes noting death and/or codes
indicating the patient was transferred out of the practice because of that person's death.(13)
An algorithm recommended by Cegedim, the administrators of THIN, was used and
identifies death codes from within the patient, medical, and administration files. This
algorithm has been used in other studies and has a sensitivity of 99.7%.(13)
Covariates of Interest
All covariates of interest were measured prior to cohort entry. The following potential
confounders were measured: Charlson comorbidity score,(20) smoking, body mass index,
blood pressure at baseline, depression, prior hospitalization in the baseline follow up period,
year of cohort entry, socioeconomic status (via Townsend deprivation score), urban versus
rural living environment, chronic kidney disease, heart disease, atrial fibrillation, diabetes,
hypertension, history of cancer, asthma, chronic obstructive pulmonary disease, and liver
disease. Furthermore, a priori we hypothesized a statistical interaction between disease
status and DMARD use. DMARDs included methotrexate, sulfasalazine, azathioprine,
leflunamide, cyclosporine, mycophenolate, hydroxychloroquine, and biologic disease
modifying agents including adalimumab, etanercept and infliximab. In the United Kingdom,
these medications can be prescribed by consultants (specialists) but should be captured by
general practitioner records with the exception of the biologic medications which are rarely
recorded.(18)
Statistical Analysis
Power calculations prior to the start of the study revealed that with 7,000 patients with PsA
and 35,000 unexposed patients, we would have 96% power to detect a hazard ratio as small
as 1.05 for patients with PsA with an average of 5 years of follow-up per patient.
Descriptive statistics were used to examine age, sex, person-time and covariate distribution
between the four groups. We fit Cox proportional hazards regression model, adjusting for
age and sex, to determine the overall hazard ratio (HR) for each group compared to the
unexposed. We then tested the hypothesized statistical interaction and fit models with the
hypothesized confounders using a purposeful selection modeling approach.(21) More detail
with regard to the modeling approach can be found in the online supplementary methods.
Log-log survival plots were generated to assess the assumption of proportionality. All
statistical analysis was performed using STATA 11.0 (College Station, TX).
Sensitivity analyses
The following sensitivity analyses were conducted: 1) Multiple imputation was performed
for body mass index and smoking status where missing and models containing these
variables were retested. 2) DMARDs were included as a time-varying covariate rather than a
stratification variable. 3) We restricted patients to only those followed for at least one year
prior to start date to ensure capture of comorbidities. 4) To examine whether missed
DMARD prescriptions would have an impact on the results, we imputed additional DMARD
users by first creating a propensity score for DMARD use and then assigning 25% of the
non-DMARD users with the highest propensity scores to DMARD use. 5) We restricted the
cohort to only those with incident disease defined as patients with at least one year of follow
up prior to the first diagnosis code. 6) Finally, we conducted an unmeasured confounder
analysis to test the assumption that there is a confounder that we are unable to measure that
may skew the results had we been able to measure this confounder. More detail with regard
to the methods used in the sensitivity analyses can be found in the online supplementary
methods.
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Ethics Board Approval
All data in this study was anonymous to the investigators. This study was approved by the
University of Pennsylvania Institutional Review Board and Cegedim's Scientific Review
Committee.
Results
Between 1994 and 2010, 8,706 patients with PsA, 41,752 with RA, and 138,424 patients
with psoriasis met inclusion criteria and 82,258 unexposed patients were randomly selected
using the described criteria. Baseline characteristics are displayed in Table 1. Age was
significantly greater among patients with RA. RA patients were predominantly female while
the male: female ratio was closer to 1:1 in the other three groups. Mean person time
contributed was 5.3 years. Median year of cohort entry was one year earlier for patients with
RA compared to the other three groups. DMARDs were prescribed to 48%, 52% and 3% of
patients with PsA, RA and psoriasis respectively. Prevalence of comorbidities was highest
among patients with RA in nearly all categories.
Among the 271,140 patients, 21,825 deaths were observed over 1,442,238 person years
(Table 2). The unadjusted incidence of mortality was highest in patients with RA (Table 3).
The interaction between disease status and history of DMARD use was statistically
significant and therefore results stratified by DMARD use are presented. The addition of
hypothesized confounders to the model did not change the model substantially. (All of the
covariates listed in the methods section were tested but individual p-values and hazard ratios
are not provided due to space restrictions). Therefore, the final model is the age- and sex-
adjusted model demonstrating increased mortality risk among patients with RA (DMARD
users HR 1.59, 95%CI: 1.52-1.66, DMARD non-users HR 1.54, 95%CI: 1.47-1.60)and
psoriasis (DMARD users HR 1.75, 95%CI: 1.56-1.95, DMARD non-users HR 1.08, 95%CI:
1.04-1.12) but no increased mortality risk among patients with psoriatic arthritis (DMARD
users HR 0.94, 95%CI: 0.80-1.10, DMARD non-users HR 1.06, 95%CI: 0.94-1.19).
Reasons for censoring (patient leaving the practice, practice stopped contributing to THIN,
and end of study in September 2010) were not significantly different among the groups (see
online supplementary Table S1). The five sensitivity analyses conducted did not change the
results of the final model (Table S2). An unmeasured confounder analysis revealed that the
even if the unmeasured confounder has a hazard ratio of 10.0 and a prevalence of 60%
among patients with PsA, the mortality risk for patients with PsA would not significantly
change (Table S3).
Conclusion
In this large population-based study, we found that patients with psoriatic arthritis did not
have a statistically significant elevation in mortality compared to the general population.
Furthermore, patients with rheumatoid arthritis and those with severe psoriasis (DMARD
users) had significantly higher mortality than the general population. The elevated all-cause
mortality risk in patients with psoriasis not utilizing DMARDs (8% increase over the general
population) is small and statistically similar to the PsA groups based on the 95% CIs. These
results are consistent with the findings of other population-based studies (3,4,22-29) and
were robust to multiple sensitivity analyses. This is the first study to directly compare the
risk of all-cause mortality in PsA to an unexposed population rather than using standardized
mortality ratios to compare to census statistics. Internal controls are generally felt to provide
a better approximation of the true effect than standardized mortality ratios.(30)
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Most previous studies of mortality in PsA have been performed within specialty clinics.
These studies have had mixed results ranging from no difference in mortality when
compared to local census statistics to a standardized mortality ratio (SMR) of 1.62 (95% CI:
1.21-2.12).(31) (Of note, the SMR was 1.36, 95%CI: 1.12-1.64, in the same cohort 10 years
later).(32) Clinic and hospital-based studies demonstrating higher mortality could be
capturing a larger proportion of patients with severe disease reflecting selection bias. In the
general population, a larger proportion of patients are likely to have mild disease. It is
possible that severity of disease is a driver of mortality risk. We were unable to test this
hypothesis in THIN, however, a sensitivity analysis demonstrated that the effect size of this
unmeasured confounder must be substantial (HR=10) in order to change the results. Finally,
it is possible that mortality has declined over time in the PsA population.(32) However,
adjusting the regression model for start year in the cohort did not change the results of the
final model.
Population-based studies using large medical record databases have tremendous advantages
in examining mortality. Consideration must be given to the choice of the unexposed or
control population in such studies as control patients may not have regular contact with their
physicians and new diagnoses or events may not be captured. It was for this reason that we
chose to include only patients who had contact with their GP around the time the matched
patient with PsA was diagnosed. Selecting patients in this way may increase the “illness
level” of patients in the unexposed group and reduce the hazard ratio for mortality in
patients in the exposed groups. Therefore, it is possible that there is a minimally increased
risk of mortality in patients with PsA. On the other hand, we included patients with
prevalent diagnoses in this study. Studies including patients with prevalent diagnoses are
generally thought to have higher mortality rates than those with incident disease.(33)
However, a sensitivity analysis including only cases with at least one year prior to the first
diagnosis code (a commonly used definition of incident disease) did not substantially change
the results.
Potential limitations of this study include misclassification of diagnoses and missing
information regarding DMARD use. Our previous validation study showed limited
misclassification of patients with a psoriatic arthritis diagnosis (i.e., a high positive
predictive value for the diagnostic code).(18) In fact, there was an even higher PPV (93%)
for patients with a diagnostic code for PsA patients with a DMARD prescription, further
decreasing the likelihood that misclassification could be the reason for the null result
(unpublished data). While we are confident in the diagnostic code for PsA, there may be
patients with PsA categorized as psoriasis only (e.g., undiagnosed cases of PsA among
patients with psoriasis).(34) It is not possible to identify the frequency of this phenomenon
in this population-based study. Population based studies such as those performed in THIN
often lack information on disease activity measures and disease characteristics. However,
the goal of this study was to examine patients with already diagnosed PsA, a more specific
cohort than all patients with possible PsA. Misclassification of the outcome is not a major
concern as mortality is unlikely to be subject to surveillance bias because it has near
complete ascertainment.(13) This population-based study draws from a larger cohort, THIN,
which is felt to be representative of the UK but may over-represent more affluent areas.(11)
However, adjusting for socio-economic status (via Townsend deprivation score) did not
change the results. Finally, use of DMARDs is difficult to model in an observational study
and can be performed in numerous ways, though all are limited by confounding by
indication.(35,36) We chose to classify patients as “ever” or “never” users because we were
using DMARDs as a stratification variable and we hypothesized that patients prescribed
therapy may be different than patients who had not been prescribed therapy. There may be
under-reporting of DMARD use in cases where the consultant is the primary prescriber,
despite the fact that this may be recorded by the GP in the medical record, and this could
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result in misclassification. However, increasing the number of DMARD users by 25% did
not significantly change the results.
In conclusion, we present the results of a large population-based study demonstrating
elevated mortality in severe psoriasis and rheumatoid arthritis but no statistically significant
elevation in mortality among patients with psoriatic arthritis. The lack of higher mortality in
patients with PsA has been previously demonstrated in smaller population-based cohorts.
Despite a lack of higher mortality, there is still significant morbidity in patients with PsA
including concomitant illnesses and impaired quality of life. Future research efforts are
needed to identify mechanisms by which we can improve comorbidities and quality of life
for patients with psoriatic arthritis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Incidence of Death
Deaths Person-Years Incidence (deaths/1000 PY)
Control 5330 431,730 12.35
PsA All 470 45,334 10.37
DMARD 159 20,377 7.80
No DMARD 311 24,958 12.46
RA All 7004 220,855 31.71
DMARD 2903 113,859 24.50
No DMARD 4101 106,996 38.33
Psoriasis All 9021 744,318 12.12
DMARD 328 14,781 22.19
No DMARD 8693 729,537 11.92
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